who medicines strategy - libdoc.who.int - World Health Organization
who medicines strategy - libdoc.who.int - World Health Organization who medicines strategy - libdoc.who.int - World Health Organization
WHO MEDICINES STRATEGY 2004-2007 | 54EO 2.4Rational use of TM/CAM byproviders and consumers bypromoting therapeutically sounduse of appropriate TM/CAMRationaleRational use of TM/CAM depends on a range offactors, including the need for adequate training,registration, and licensing of providers, properuse of products of assured quality, and provisionof scientific information and guidance for thepublic.The efficacy and safe practice of TM/CAMtherapies are closely linked to the qualification ofpractitioners. Good practice in TM is dependanton proper training, the registration of practitioners,and the licensing of TM/CAM practice.ProgressIn 2002, WHO published Volume 2 of the WHOmonographs on selected medicinal plants,containing 30 monographs. Volume 3, providingan additional 31 monographs is in the finalstage of production. The European Commissionrecommends WHO monographs to its membersas an authoritative reference on the quality, safety,and efficacy of medicinal plants. Today, over 12other countries use WHO monographs for theirregulation and registration of herbal medicines.In addition, several countries, including Armenia,Benin, Mexico, Malaysia, South Africa andViet Nam, have developed their own nationalmonographs based on the WHO format. In2003, WHO developed guidelines for consumerinformation on the appropriate use of TM/CAM.ChallengesA range of health care professionals serve asqualified providers of TM/CAM, operating withineach country’s national health care deliverysystem and legislative framework. However,many countries do not have a national schemefor training, education, qualification, licensing,and registration of providers of TM/CAM. As aresult, providers of TM/CAM medicines, such asphysicians, nurses and pharmacists, may havelittle training and understanding of how herbalmedicines, for example, impact on the health ofpatients who are often taking other prescriptionmedicines as well. This information is alsorelevant when diagnostic and treatment decisionsare made.
Number of Member StatesCOMPONENTS OF THE STRATEGY | 55Figure 12:Growth of National Institutes60504030201001999 2003Source: Interim summary analysis of WHO globalsurvey on national policy on TM/CAM, 2002- 2003.Traditional medicines are increasingly used outsidethe confines of traditional culture and far beyondtraditional geographical areas, without properknowledge of their context and use. Moreover,they are also used in different doses, extractedin different ways, and used for indications whichare different from their traditional intended use.To compound the problem, contrary to their usein the traditional context, traditional medicinesare now often used in combination with othermedicines – a practice which has become a safetyconcern.There is a widespread misconception that ‘natural’means ‘safe’ and many believe that remedies ofnatural origin carry no risk. Although a great dealof information on TM/CAM is available through avariety of channels, many consumers are unableto evaluate and select reliable information inorder to make a decision on the use of TM/CAMproducts for self-medication.Meeting the challenges 2004-2007Over the next four years WHO will:> continue to develop basic training guidelineson major forms of TM/CAM, includingchiropractice, herbal medicines, and manualtherapies.> continue to develop authoritative referencesfor Member States, such as the WHOmonographs on selected medicinal plants.> organize an inter-regional workshop toimplement WHO guidelines on proper use ofTM/CAM by consumers, to strengthen nationalcapacity in providing reliable consumerinformation on TM/CAM.OUTCOME INDICATORS1999 2003 2007#REPORTING % TARGET#REPORTING % TARGETNo. of countries with national research institute in the field 19 na na 56/127 e 44% e 51%of TM/CAM e
- Page 23: MEDICINESAND PUBLIC HEALTH
- Page 26 and 27: WHO MEDICINES STRATEGY 2004-2007 |
- Page 28 and 29: WHO MEDICINES STRATEGY 2004-2007 |
- Page 30 and 31: WHO MEDICINES STRATEGY 2004-2007 |
- Page 32 and 33: WHO MEDICINES STRATEGY 2004-2007 |
- Page 34 and 35: WHO MEDICINES STRATEGY 2004-2007 |
- Page 36 and 37: WHO MEDICINES STRATEGY 2004-2007 |
- Page 38 and 39: WHO MEDICINES STRATEGY 2004-2007 |
- Page 40 and 41: WHO MEDICINES STRATEGY 2004-2007 |
- Page 42 and 43: WHO MEDICINES STRATEGY 2004-2007 |
- Page 44 and 45: WHO MEDICINES STRATEGY 2004-2007 |
- Page 46 and 47: WHO MEDICINES STRATEGY 2004-2007 |
- Page 48 and 49: WHO MEDICINES STRATEGY 2004-2007 |
- Page 50 and 51: WHO MEDICINES STRATEGY 2004-2007 |
- Page 52 and 53: WHO MEDICINES STRATEGY 2004-2007 |
- Page 54 and 55: WHO MEDICINES STRATEGY 2004-2007 |
- Page 56 and 57: WHO MEDICINES STRATEGY 2004-2007 |
- Page 58 and 59: WHO MEDICINES STRATEGY 2004-2007 |
- Page 60 and 61: WHO MEDICINES STRATEGY 2004-2007 |
- Page 62 and 63: WHO MEDICINES STRATEGY 2004-2007 |
- Page 64 and 65: WHO MEDICINES STRATEGY 2004-2007 |
- Page 68 and 69: WHO MEDICINES STRATEGY 2004-2007 |
- Page 70 and 71: WHO MEDICINES STRATEGY 2004-2007 |
- Page 72 and 73: WHO MEDICINES STRATEGY 2004-2007 |
- Page 74 and 75: WHO MEDICINES STRATEGY 2004-2007 |
- Page 76 and 77: WHO MEDICINES STRATEGY 2004-2007 |
- Page 78 and 79: WHO MEDICINES STRATEGY 2004-2007 |
- Page 80 and 81: WHO MEDICINES STRATEGY 2004-2007 |
- Page 82 and 83: WHO MEDICINES STRATEGY 2004-2007 |
- Page 84 and 85: WHO MEDICINES STRATEGY 2004-2007 |
- Page 86 and 87: WHO MEDICINES STRATEGY 2004-2007 |
- Page 88 and 89: WHO MEDICINES STRATEGY 2004-2007 |
- Page 90 and 91: WHO MEDICINES STRATEGY 2004-2007 |
- Page 92 and 93: WHO MEDICINES STRATEGY 2004-2007 |
- Page 94 and 95: WHO MEDICINES STRATEGY 2004-2007 |
- Page 96 and 97: WHO MEDICINES STRATEGY 2004-2007 |
- Page 98 and 99: WHO MEDICINES STRATEGY 2004-2007 |
- Page 100 and 101: WHO MEDICINES STRATEGY 2004-2007 |
- Page 102 and 103: WHO MEDICINES STRATEGY 2004-2007 |
- Page 104 and 105: WHO MEDICINES STRATEGY 2004-2007 |
- Page 106 and 107: WHO MEDICINES STRATEGY 2004-2007 |
- Page 108 and 109: WHO MEDICINES STRATEGY 2004-2007 |
- Page 110 and 111: WHO MEDICINES STRATEGY 2004-2007 |
- Page 112 and 113: WHO MEDICINES STRATEGY 2004-2007 |
- Page 114 and 115: WHO MEDICINES STRATEGY 2004-2007 |
WHO MEDICINES STRATEGY 2004-2007 | 54EO 2.4Rational use of TM/CAM byproviders and consumers bypromoting therapeutically sounduse of appropriate TM/CAMRationaleRational use of TM/CAM depends on a range offactors, including the need for adequate training,registration, and licensing of providers, properuse of products of assured quality, and provisionof scientific information and guidance for thepublic.The efficacy and safe practice of TM/CAMtherapies are closely linked to the qualification ofpractitioners. Good practice in TM is dependanton proper training, the registration of practitioners,and the licensing of TM/CAM practice.ProgressIn 2002, WHO published Volume 2 of the WHOmonographs on selected medicinal plants,containing 30 monographs. Volume 3, providingan additional 31 monographs is in the finalstage of production. The European Commissionrecommends WHO monographs to its membersas an authoritative reference on the quality, safety,and efficacy of medicinal plants. Today, over 12other countries use WHO monographs for theirregulation and registration of herbal <strong>medicines</strong>.In addition, several countries, including Armenia,Benin, Mexico, Malaysia, South Africa andViet Nam, have developed their own nationalmonographs based on the WHO format. In2003, WHO developed guidelines for consumerinformation on the appropriate use of TM/CAM.ChallengesA range of health care professionals serve asqualified providers of TM/CAM, operating withineach country’s national health care deliverysystem and legislative framework. However,many countries do not have a national schemefor training, education, qualification, licensing,and registration of providers of TM/CAM. As aresult, providers of TM/CAM <strong>medicines</strong>, such asphysicians, nurses and pharmacists, may havelittle training and understanding of how herbal<strong>medicines</strong>, for example, impact on the health ofpatients <strong>who</strong> are often taking other prescription<strong>medicines</strong> as well. This information is alsorelevant when diagnostic and treatment decisionsare made.
Change language